Institution RFA PI Name Award Value University of California, Los Angeles Clinical Trial Stage Projects Donald Kohn A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease $7,083,364 University of California, Los Angeles Disease Team Therapy Development - Research Antoni Ribas Genetic Re-programming of Stem Cells to Fight Cancer $19,875,776 University of California, Los Angeles Tools and Technologies II Martin Martin Pluripotent and Somatic Stem Cell Models to Study Inherited Diarrheal Disorders $1,783,250 University of California, Los Angeles Disease Team Therapy Development III Dennis Slamon A Phase I dose escalation and expansion clinical trial in patients with advanced solid tumors $6,924,317 University of California, Los Angeles Basic Biology III Ali Nsair Characterization and Engineering of the Cardiac Stem Cell Niche $1,163,618 University of California, Los Angeles Basic Biology III William Lowry Molecular determinants of accurate differentiation from human pluripotent stem cells $677,115 University of California, Los Angeles Early Translational IV Zack Jerome Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection $4,925,166 University of California, Los Angeles Early Translational IV Gerald Lipshutz Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders $1,801,629 University of California, Los Angeles Tools and Technologies III Leif Havton Development of a Relevant Pre-Clinical Animal Model as a Tool to Evaluate Human Stem Cell-Derived Replacement Therapies for Motor Neuron Injuries and Degenerative Diseases $1,308,711 University of California, Los Angeles Early Translational IV Donald Kohn Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells $1,652,076 University of California, Los Angeles Research Leadership John Chute Niche-Focused Research: Discovery & Development of Hematopoietic Regenerative Factors $5,174,715 University of California, Los Angeles Early Translational II Leif Havton Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $75,628 University of California, Los Angeles New Faculty Physician Scientist Reza Ardehali Preclinical evaluation of human embryonic stem cell-derived cardiovascular progenitors $2,930,388 University of California, Los Angeles Disease Team Therapy Development III Donald Kohn Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease $13,145,465 University of California, Los Angeles Alpha Stem Cell Clinics John Adams Alpha Stem Cell Clinic (ASCC) Consortium $8,000,000 University of California, Los Angeles Early Translational II Noriyuki Kasahara Stem cell-based carriers for RCR vector delivery to glioblastoma $3,340,625 University of California, Los Angeles Tools and Technologies III Carla Koehler A small molecule tool for reducing the malignant potential in reprogramming human iPSCs and ESCs $1,283,900 University of California, Los Angeles New Faculty Physician Scientist Ali Nsair Human Induced Pluripotent Stem Cell-Derived Cardiovascular Progenitor Cells for Cardiac Cell Therapy. $3,004,315 University of California, Los Angeles Basic Biology V Bennett Novitch In vitro modeling of human motor neuron disease $1,148,758 University of California, Los Angeles Early Translational from Disease Team Conversion Stanley Nelson Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy $1,823,545 University of California, Los Angeles Early Translational II Sophie Deng Regeneration of Functional Human Corneal Epithelial Progenitor Cells $699,983 University of California, Los Angeles Tissue Collection for Disease Modeling Brigitte Gomperts Using human induced pluripotent stem cells to improve our understanding of Idiopathic Pulmonary Fibrosis $811,231 University of California, Los Angeles Research Training II Kenneth Dorshkind CIRM Research Training Program II $7,898,444 Stanford University Disease Team Research I Gary Steinberg Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke $18,026,648 Children's Hospital of Orange County Early Translational III Philip Schwartz Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease $4,272,774 University of California, Los Angeles Basic Biology V Denis Evseenko Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes $1,146,468 University of California, Los Angeles SEED Grant Michael Teitell Role of Mitochondria in Self-Renewal Versus Differentiation of Human Embryonic Stem Cells $543,274 University of California, Los Angeles Shared Labs Owen Witte CIRM Shared Research Laboratories $1,751,297 University of California, Los Angeles Early Translational from Disease Team Conversion Irvin Chen HPSC based therapy for HIV disease using RNAi to CCR5. $1,505,000 University of California, Los Angeles New Faculty II Brigitte Gomperts Stem Cells in Lung Cancer $2,381,572 University of California, Los Angeles Tools and Technologies II Stanley Carmichael Development of a Hydrogel Matrix for Stem Cell Growth and Neural Repair after Stroke $1,825,613 University of California, Los Angeles Early Translational IV Robert Reiter Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells $4,075,668 University of California, Los Angeles Tools and Technologies III James Dunn Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction $1,818,751 University of California, Los Angeles Basic Biology V Lili Yang Differentiation of Human Hematopoietic Stem Cells into iNKT Cells $614,400 University of California, Los Angeles New Faculty Physician Scientist Ali Nsair Human Induced Pluripotent Stem Cell-Derived Cardiovascular Progenitor Cells for Cardiac Cell Therapy. $0 University of California, Los Angeles Basic Biology V Samantha Butler Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate $545,962 University of California, Los Angeles Basic Biology III Yi Sun Studying neurotransmission of normal and diseased human ES cell-derived neurons in vivo $1,382,400 University of California, Los Angeles Early Translational II Bruno Peault Harnessing native fat-residing stem cells for bone regeneration $5,359,076 University of California, Los Angeles New Faculty II Antoni Ribas Stem Cells for Immune System Regeneration to Fight Cancer $3,072,000 University of California, Los Angeles Basic Biology I Michael Teitell Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer $1,323,029 University of California, Los Angeles New Faculty I Kathrin Plath In vitro reprogramming of mouse and human somatic cells to an embryonic state $2,229,427 University of California, Los Angeles SEED Grant Irvin Chen Genetic modification of the human genome to resist HIV-1 infection and/or disease progression $616,800 University of California, Los Angeles Training Grant I-1 Owen Witte CIRM Type I Comprehensive Training Program $3,660,398 University of California, Los Angeles Tools and Technologies I Hsian-Rong Tseng Microfluidic Platform for Screening Chemically Defined Conditions that Facilitate Clonal Expansion of Human Pluripotent Stem Cells $914,096 University of California, Los Angeles Basic Biology III Kathrin Plath Discovery of mechanisms that control epigenetic states in human reprogramming and pluripotent cells $1,364,598 University of California, Los Angeles SEED Grant Hanna Mikkola Improving microenvironments to promote hematopoietic stem cell development from human embryonic stem cells $550,241 University of California, Los Angeles Basic Biology II Douglas Black Programs of alternative splicing regulation by polypyrimidine tract binding protein $1,344,562 University of California, Los Angeles Major Facilities Gene Block UCLA CIRM Institute $19,854,900 University of California, Los Angeles SEED Grant Siavash Kurdistani Cellular epigenetic diversity as a blueprint for defining the identity and functional potential of human embryonic stem cells $549,698 University of California, Los Angeles Tools and Technologies I Michael Phelps Novel Tools and Technologies for Translational PET Imaging of Cell-based Therapies $914,039 University of California, Los Angeles Disease Team Research I Dennis Slamon THERAPEUTIC OPPORTUNITIES TO TARGET TUMOR INITIATING CELLS IN SOLID TUMORS $19,979,660 University of California, Los Angeles Comprehensive Grant Gay Crooks Regulated Expansion of Lympho-hematopoietic Stem and Progenitor Cells from Human Embryonic Stem Cells (hESC) $1,653,416 University of California, Los Angeles Basic Biology II Yong Kim Novel Mechanism in Self-Renewal/Differentiation of Human Embryonic Stem Cells $1,259,371 University of California, Los Angeles Tools and Technologies II Richard Gatti Use of hiPSCs to develop lead compounds for the treatment of genetic diseases $1,833,054 University of California, Los Angeles Disease Team Planning Irvin Chen Stem Cell Therapy for AIDS- Disease Team Planning $51,490 University of California, Los Angeles SEED Grant Noriyuki Kasahara Down-Regulation of Alloreactive Immune Responses to hES Cell-Derived Graft Tissues $399,239 University of California, Los Angeles Transplantation Immunology Gay Crooks Engineering Thymic Regeneration to Induce Tolerance $1,235,445 University of California, Los Angeles Disease Team Research I Donald Kohn Stem Cell Gene Therapy for Sickle Cell Disease $8,833,695 University of California, Los Angeles Basic Biology III Shuo Lin Etsrp/ER71 mediated stem cell differentiation into vascular lineage $1,382,400 University of California, Los Angeles Tools and Technologies III Hanna Mikkola A suite of engineered human pluripotent stem cell lines to facilitate the generation of hematopoietic stem cells $1,382,400 University of California, Los Angeles Comprehensive Grant Zack Jerome Human Embryonic Stem Cell Therapeutic Strategies to Target HIV Disease $2,401,903 University of California, Los Angeles Basic Biology II Benhur Lee The EphrinB2/EphB4 axis in regulating hESC pluripotency and differentiation $1,371,936 University of California, Los Angeles Disease Team Planning Stanley Carmichael Development of a Stem Cell Therapy to Promote Functional Recovery in Stroke $42,748 University of California, Los Angeles SEED Grant Zoran Galic Genetic Enhancement of the Immune Response to Melanoma via hESC-derived T cells $616,800 University of California, Los Angeles Basic Biology IV Kathrin Plath Understanding the status of the X chromosomes in human ESCs and preimplantation embryos $1,382,400 University of California, Los Angeles Basic Biology I Robb Maclellan Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate $917,667 University of California, Los Angeles New Faculty I Dana Jones Characterization of mechanisms regulating de-differentiation and the re-acquisition of stem cell identity $382,773 University of California, Los Angeles Disease Team Research I Irvin Chen HPSC based therapy for HIV disease using RNAi to CCR5. $9,905,604 University of California, Los Angeles Comprehensive Grant Guoping Fan Epigenetic gene regulation during the differentiation of human embryonic stem cells: Impact on neural repair $2,412,995 University of California, Los Angeles Basic Biology III Gay Crooks Forming the Hematopoietic Niche from Human Pluripotent Stem Cells $1,252,857 University of California, Los Angeles Shared Labs Scott Waugh CIRM Shared Research Laboratories $2,000,000 University of California, Los Angeles Basic Biology IV Owen Witte Trop2 dependent and independent mechanisms of self-renewal in human cancer stem cells $1,254,960 University of California, Los Angeles Basic Biology I Luisa Iruela-Arispe Molecular Characterization and Functional Exploration of Hemogenic Endothelium $1,371,477 University of California, Los Angeles New Faculty I Siavash Kurdistani Epigenetics in cancer stem cell initiation and clinical outcome prediction $3,063,450 University of California, Los Angeles New Cell Lines Zack Jerome Generation of clinical grade human iPS cells $1,341,000 University of California, Los Angeles Disease Team Therapy Planning I Antoni Ribas Genetic Re-programming of Stem Cells to Fight Cancer $97,785 University of California, Los Angeles Early Translational I Gabriel Travis Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration $5,487,136 University of California, Los Angeles Early Translational II Sophie Deng Regeneration of Functional Human Corneal Epithelial Progenitor Cells $1,524,947 University of California, Los Angeles SEED Grant William Lowry Modeling Human Embryonic Development with Human Embryonic Stem Cells $528,096 University of California, Los Angeles Basic Biology I Bennett Novitch Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons $1,229,922 University of California, Los Angeles New Faculty I Hanna Mikkola Mechanisms of Hematopoietic stem cell Specification and Self-Renewal $2,286,900 University of California, Los Angeles New Cell Lines Amander Clark Generation of Pluripotent Cell Lines from Human Embryos $1,168,501 University of California, Los Angeles Disease Team Therapy Planning I Stanley Nelson Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy $68,947